SLU-PP-332

Source-reported examples · not treatment recommendations

Amount

25–50 mg/kg per administration in cited mouse experiments

Frequency

Twice daily

Cycle / observation period

8 weeks according to the source

Route / research model

Intraperitoneal in mice

Animal research only. These are not human amounts or a human injection route. The preparation example is not independently validated.

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Available source strength: 5 mg. A body-weight-dependent animal exposure or topical batch concentration cannot be converted into a generic human vial count.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

• In the original mouse work, SLU-PP-332 increased oxidative type IIa muscle fibers and exercise capacity, and the reported acute exercise-associated program depended on ERR alpha. Several authors disclosed stockholding in Myonid Therapeutics. ^[1]
• A later study evaluated SLU-PP-332 in diet-induced obese mice and genetically obese ob/ob mice. The investigators reported greater energy expenditure and fat oxidation, less fat accumulation and improved insulin-sensitivity measures. This was a preclinical investigation of metabolic outcomes, not a comparison against a human weight-management treatment. ^[2]
• Wang and colleagues found lower ERR expression in aging human and mouse kidney material and evaluated SLU-PP-332 treatment in 21-month-old mice. Eight weeks of treatment improved selected measures including albuminuria, podocyte loss, mitochondrial dysfunction and inflammatory signaling. The paper also investigated STING inhibition as a separate intervention. ^[3]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 12 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. Original experimental report and disclosures
2. Original metabolic paper
3. 2023 kidney investigation
4. Circulation (2024)Further reading · Listed in reference bibliography.
5. CDC (2024)General guidance · Listed in reference bibliography.
6. CDC (2024)General guidance · Listed in reference bibliography.
7. Advanced Drug Delivery Reviews (2023)Further reading · Listed in reference bibliography.
8. Journal of Chromatography B (2023)Further reading · Listed in reference bibliography.
9. Clinical Chemistry (2016)Further reading · Listed in reference bibliography.
10. Journal of Pharmaceutical Sciences (2012)Further reading · Listed in reference bibliography.
11. Acta Pharmacologica Sinica (2015)Further reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.